BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $394.00. The ...
BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $270.00. The ...
Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
FiscalNote Holdings Inc (NOTE) stock saw a modest uptick, ending the day at $1.25 which represents a slight increase of $0.21 or 20.19% from the prior close of $1.04. The stock opened at $1.03 and ...
FREYR Battery (NYSE:FREY) rallied for a second consecutive session after BTIG upgraded the stock to a Buy rating. Last month, FREY announced it was acquiring a 5GW solar module facility in Texas ...
BTIG Research’s target price would suggest a potential upside of 120.82% from the stock’s current price. Several other equities research analysts have also recently weighed in on the stock.
BTIG downgraded Lennar (LEN) to Neutral from Buy and removed the firm’s prior price target after the company missed Q4 EPS and guided Q1 EPS 31% below the prior FactSet consensus. The firm ...
On Friday, BTIG reaffirmed its Buy rating and $10.00 price target for Humacyte (NASDAQ:HUMA), currently trading at $3.46, following the Food and Drug Administration's approval of the company's ...